Docetaxel as Second Line After Failure of Gemcitabine/Cisplatin Regimen in Advanced and/or Metastatic Urinary Bladder Cancer Patients in Egypt

Research in Oncology
doi 10.21608/resoncol.2013.881
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Egypts Presidential Specialized Council for Education and Scientific Research

Related search

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced and or Metastatic Bilharzial Urothelial Carcinoma of the Bladder in Egypt.

Research in Oncology
2011English

Triplet Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin as Second-Line Therapy for Advanced Urothelial Carcinoma

Modern Chemotherapy
2013English

Biweekly Cisplatin and Gemcitabine in Patients With Advanced Biliary Tract Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Triplet Chemotherapy Combination With Cisplatin, Gemcitabine and Docetaxel in Patients With Chemotherapy‑naive Advanced Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2013English

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients

Korean Journal of Internal Medicine
Internal Medicine
2007English

Phase I Dose-Escalation Study of Copanlisib in Combination With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

An Open-Label Feasibility Study of Nintedanib Combined With Docetaxel in Japanese Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of First-Line Chemotherapy

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

Efficacy of Fluoropyrimidine-Based Chemotherapy in Patients With Advanced Biliary Tract Cancer After Failure of Gemcitabine Plus Cisplatin: Retrospective Analysis of 321 Patients

British Journal of Cancer
Cancer ResearchOncology
2017English

Phase II Trial of Vatalanib in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma After First-Line Gemcitabine Therapy (PCRT O4-001)

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy